PPARG and endothelial dysfunction: Pioglitazone, a thiazolidinedione, is a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist which in addition to its insulin sensitizing action, is also reported to have many favorable effects on endothelial dysfunction (including antiatherogenic properties [13, 14]) and future cardiovascular events in both diabetic and non-diabetic patients [15, 16].